Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions
A recent analysis of antibiotics approved between 1999 and 2014, conducted by researchers at the Norwegian Institute of Public Health; the University of Oslo; the Center for Disease Dynamics, Economics & Policy (CDDEP); and Boston University, showed a lack of novelty and diversity regarding target pathogens and indications and a failure to address the most urgent resistance threats, including resistant Gram-negative bacteria. A global research and development strategy should incentivize development of broad-spectrum antibiotics for critically ill patients, as well as therapeutic alternatives to antibiotics, decreasing our dependence on traditional, small-molecule antibiotics.
Emerging Antimicrobials and Diagnostics in AMR 2019
International Matchmaking Symposium on 20 November, 2019 in Amsterdam, The Netherlands.